Treatment options for hypertension in pregnancy and puerperium

References

• American College of Obstetricians and Gynecologists and Task Force on Hypertension in Pregnancy.. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol. 2013;122(5):1122–1131.
   PubMed Web of Science ®Google Scholar
• Wallis AB, Saftlas AF, Hsia J, et al. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens. 2008;21(5):521–526.
   PubMed Web of Science ®Google Scholar
• Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):391–403.
   PubMed Web of Science ®Google Scholar
• Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ. 2010;341:c2207.
   PubMedGoogle Scholar
• Magee LA, Pels A, Helewa M, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014;4(2):105–145.
   PubMed Web of Science ®Google Scholar
• Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014;2:CD002252.
   PubMed Web of Science ®Google Scholar
• Tita AT, Sibai BM, Oparil S. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(24):2366–2367.
   PubMed Web of Science ®Google Scholar
• Magee LA, Singer J, Von Dadelszen P. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407–417.
   PubMed Web of Science ®Google Scholar
• Clark SM, Dunn HE, Hankins GD. A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy. Semin Perinatol. 2015;39(7):548–555.
   PubMed Web of Science ®Google Scholar
• Tsatsaris V, Cabrol D, Carbonne B. Pharmacokinetics of tocolytic agents. Clin Pharmacokinet. 2004;43(13):833–844.
   PubMed Web of Science ®Google Scholar
• Smith P, Anthony J, Johanson R. Nifedipine in pregnancy. BJOG. 2000;107(3):299–307.
   PubMed Web of Science ®Google Scholar
• Fischer JH, Sarto GE, Hardman J, et al. Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. Clin Pharmacokinet. 2014;53(4):373–383.
   PubMed Web of Science ®Google Scholar
• Saotome T, Minoura S, Terashi KEA. Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. J Clin Pharmacol. 1993;33(10):979–988.
   PubMed Web of Science ®Google Scholar
• Magee LA, Von Dadelszen P, Singer J, et al. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG. 2016;123(7):1143–1151.
   Web of Science ®Google Scholar
• Anderson GD, Carr DB. Effect of pregnancy on the pharmacokinetics of antihypertensive drugs. Clin Pharmacokinet. 2009;48(3):159–168.
   PubMed Web of Science ®Google Scholar
• Wright JM, Orozco-Gonzalez M, Polak G, et al. Duration of effect of single daily dose methyldopa therapy. Br J Clin Pharmacol. 1982;13(6):847–854.
   PubMed Web of Science ®Google Scholar
• Sibai BM, Barton JR, Akl S, et al. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol. 1992;167(4 Pt 1):879–884.
   PubMed Web of Science ®Google Scholar
• van Vliet EO, Nijman TA, Schuit E, et al. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. Lancet. 2016;387(10033):2117–2124.
   PubMed Web of Science ®Google Scholar
• Slim R, Ben Salem C, Hmouda H, et al. Hepatotoxicity of alpha-methyldopa in pregnancy. J Clin Pharm Ther. 2010;35(3):361–363.
   PubMed Web of Science ®Google Scholar
• Bortolus R, Ricci E, Chatenoud L, et al. Nifedipine administered in pregnancy: effect on the development of children at 18 months. BJOG. 2000;107(6):792–794.
   PubMed Web of Science ®Google Scholar
• Davis RL, Andrade S, Platt R. Risk of congenital malformations among infants exposed to antidepressants during pregnancy. Pharmacoepidemiol Drug Saf. 2008;17(4):423.
   PubMed Web of Science ®Google Scholar
• Giannubilo SR, Bezzeccheri V, Cecchi S, et al. Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. Arch Gynecol Obstet. 2012;286(3):637–642.
   PubMed Web of Science ®Google Scholar
• Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2003;(3):CD002863.
   Google Scholar
• Xie RH, Guo Y, Krewski D, et al. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol. 2014;175:124–128.
   PubMed Web of Science ®Google Scholar
• Cockburn J, Moar VA, Ounsted M, et al. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1(8273):647–649.
   PubMed Web of Science ®Google Scholar
• Spong CY, Mercer BM, D’alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol. 2011;118(2 Pt 1):323–333.
   PubMed Web of Science ®Google Scholar
• Khashu M, Narayanan N, Bhargava S, et al. Perinatal outcomes associated with preterm birth at 33 to 36 weeks’ gestation: a population-based cohort study. Pediatrics. 2009;123(1):109–113.
   PubMed Web of Science ®Google Scholar
• Backes CH, Markham K, Moorehead P, et al. Maternal preeclampsia and neonatal outcomes. J Pregnancy. 2011;2011:214365.
   PubMedGoogle Scholar
• Abalos E, Cuesta C, Grosso AL, et al. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1–7.
   PubMed Web of Science ®Google Scholar
• Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516):1066–1074.
   PubMed Web of Science ®Google Scholar
• Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57(12):1404–1423.
   PubMed Web of Science ®Google Scholar
• Irgens HU, Reisaeter L, Irgens LM, et al. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001;323(7323):1213–1217.
   PubMed Web of Science ®Google Scholar
• Pryde PG, Sedman AB, Nugent CE, et al. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol. 1993;3(9):1575–1582.
   PubMed Web of Science ®Google Scholar
• Hale TW, Rowe HE. Medications & mothers’ Milk 2014. 16th ed. Plano:Hale;2014. Print
   Google Scholar
• Moussa HN, Arian SE, Sibai BM. Management of hypertensive disorders in pregnancy. Womens Health (Lond Engl). 2014;10(4):385–404.
   PubMedGoogle Scholar
• Kim MY, Buyon JP, Guerra MM, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016;214(1):108e1– e14.
   Web of Science ®Google Scholar
• Martin A, Krishna I, Badell M, et al. Can the quantity of cell-free fetal DNA predict preeclampsia: a systematic review. Prenat Diagn. 2014;34(7):685–691.
   PubMed Web of Science ®Google Scholar
• Textoris J, Ivorra D, Ben Amara AS, et al. Evaluation of current and new biomarkers in severe preeclampsia: a microarray approach reveals the VSIG4 gene as a potential blood biomarker. PLoS One. 2013;8(12):e82638.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt W, Rana S, Stepan H. The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med. 2013;41(5):511–516.
   PubMed Web of Science ®Google Scholar
• Rana S, Hacker MR, Modest AM, et al. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension. 2012;60(2):451–458.
   PubMed Web of Science ®Google Scholar
• Zhang H, Yang D, Yang H, et al. [Effect on conception and offspring development in female parenatal rats following intratracheal instillation of nano-C/ZnO and C-ZnO composite nanoparticles]. Wei Sheng Yan Jiu = J Hyg Res. 2008;37(6):654–656.
   PubMedGoogle Scholar
• Guttmacher AE, Maddox YT, Spong CY. The human placenta project: placental structure, development, and function in real time. Placenta. 2014;35(5):303–304.
   PubMed Web of Science ®Google Scholar